AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Warner-Lambert Company and Rhone-Poulenc Rorer Inc. (RPR) announced an agreement that will allow RPR to co-develop and co-promote the advanced quinolone antibacterial sparfloxacin in the U.S. and Canada.
Warner-Lambert will continue to study sparfloxacin in the U.S. for the treatment of Mycobacterium avium complex (MAC) in patients with AIDS. MAC is the most common bacterial infection in AIDS patients.
Sparfloxacin will soon enter Phase III clinical trials in the U.S. as a treatment for community acquired infections. The compound's investigational indications are community acquired pneumonia, acute …